Lixisenatide: GLP-1 Agonist Profile

Lixisenatide represents a distinctive approach among glucagon-like peptide-1 (GLP-1) receptor agonists: a short-acting peptide designed for once-daily administration that exerts its primary effects during the period immediately following meals. Approved by the FDA in 2016 under the brand name Adlyxin (Lyxumia in Europe), this 44-amino acid peptide was developed by Sanofi to target postprandial glucose excursions through pronounced gastric slowing rather than sustained 24-hour GLP-1 receptor activation.

Structurally derived from exendin-4—the peptide originally isolated from Gila monster venom—lixisenatide incorporates specific modifications that increase its binding affinity to GLP-1 receptors approximately fourfold compared to native GLP-1. Despite FDA approval and completion of a comprehensive clinical trial program involving over 4,500 patients, lixisenatide was voluntarily withdrawn from the U.S. market in January 2023 due to business considerations, though it remains available in other markets including Europe and Japan.

This profile examines lixisenatide's molecular structure, mechanisms of action, clinical evidence from the GetGoal trial program and ELIXA cardiovascular outcomes study, and its place within the broader landscape of GLP-1 therapeutics.

Quick Facts
What Is Lixisenatide?
How Lixisenatide Works: Mechanisms of Action
Clinical Research and Evidence
Administration and Dosing
Safety Profile and Side Effects
Legal and Regulatory Status
Frequently Asked Questions
The Bottom Line
References

Quick Facts

Property	Details
Full Chemical Name	Des-38-proline-exendin-4(1-39)-peptidyl-penta-L-lysyl-L-lysinamide
Brand Names	Adlyxin (US, discontinued), Lyxumia (Europe)
Classification	Short-acting GLP-1 receptor agonist
Amino Acids	44 amino acids, C-terminal amidated
Molecular Weight	4858.5 Da
Molecular Formula	C₂₁₅H₃₄₇N₆₁O₆₅S
Half-Life	3 hours (range: 2.6-4.3 hours)
Manufacturer	Sanofi
FDA Approval	2016 (withdrawn from US market 2023)
Administration	Once-daily subcutaneous injection
Dosing	10 μg (initiation) → 20 μg (maintenance)
Primary Effect	Postprandial glucose reduction via gastric slowing

What Is Lixisenatide?

Lixisenatide is a synthetic peptide analog designed to mimic and amplify the effects of native glucagon-like peptide-1 (GLP-1), an incretin hormone that plays a central role in glucose homeostasis. As a member of the GLP-1 receptor agonist class, lixisenatide was developed to help individuals with type 2 diabetes achieve better glycemic control, particularly in the postprandial period—the hours immediately following meals when blood glucose levels typically spike.

Structural Foundation

The peptide's structure is based on exendin-4, a 39-amino acid peptide originally isolated from the saliva of the Gila monster (Heloderma suspectum). Exendin-4 shares approximately 53% amino acid sequence homology with human GLP-1 but exhibits significantly greater resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), the enzyme that rapidly inactivates native GLP-1 within minutes of secretion.

Lixisenatide incorporates two key structural modifications to the exendin-4 template:

Deletion of proline at position 38 from the original exendin-4 sequence
Addition of six lysine residues at the C-terminus, followed by terminal amidation

These modifications extend the peptide to 44 amino acids and confer several functional advantages. The six-lysine tail increases the molecule's overall positive charge, which enhances binding affinity to the GLP-1 receptor. Studies demonstrate that lixisenatide exhibits approximately fourfold greater binding affinity than native GLP-1, and 2.5-fold greater affinity than exenatide (the synthetic version of exendin-4), while showing 12.5-fold greater affinity than liraglutide.

Pharmacological Classification

Lixisenatide is classified as a short-acting, prandial GLP-1 receptor agonist. This designation distinguishes it from long-acting agents like semaglutide and dulaglutide, which maintain more consistent receptor activation over 24 hours or longer. The short-acting profile of lixisenatide results in a plasma half-life of approximately 3 hours, with peak concentrations occurring 1-3.5 hours after subcutaneous injection.

This pharmacokinetic profile makes lixisenatide particularly suited for controlling the rapid glucose excursions that occur after meals, rather than providing continuous around-the-clock glucose lowering. The drug's effects are most pronounced during the 4-6 hour window following administration, aligning with the postprandial period when glucose absorption from the gastrointestinal tract is most active.

Development and Market Position

Lixisenatide was developed by Sanofi as part of a broader strategy to offer GLP-1-based therapies for type 2 diabetes. The drug underwent extensive clinical evaluation through the GetGoal clinical trial program, which enrolled more than 4,500 patients across 13 multinational trials. This program assessed lixisenatide's efficacy both as monotherapy and in combination with commonly prescribed oral antidiabetic medications and basal insulin.

The European Medicines Agency (EMA) approved lixisenatide in 2013 under the brand name Lyxumia, followed by FDA approval in July 2016 under the brand name Adlyxin. However, despite regulatory approval and demonstrated clinical efficacy, Sanofi announced in October 2022 that it would discontinue U.S. sales of Adlyxin effective January 1, 2023. The company cited business reasons for this decision, including market competition from newer GLP-1 agents with more convenient dosing regimens (such as once-weekly options) and the availability of alternative treatments. Lixisenatide remains available in European and Asian markets.

How Lixisenatide Works: Mechanisms of Action

Lixisenatide's therapeutic effects arise from activation of GLP-1 receptors distributed throughout multiple organ systems. While it shares the basic mechanism of all GLP-1 agonists—enhanced glucose-dependent insulin secretion—its short-acting pharmacokinetic profile produces a distinct pattern of effects that differentiate it from longer-acting agents in the class.

GLP-1 Receptor Activation

The GLP-1 receptor is a G-protein coupled receptor (GPCR) belonging to the class B family. When lixisenatide binds to this receptor, it triggers a signaling cascade initiated by activation of the Gs protein subunit. This leads to stimulation of adenylyl cyclase, which converts ATP to cyclic AMP (cAMP). Elevated intracellular cAMP levels activate two principal downstream effectors:

Protein kinase A (PKA) – Phosphorylates numerous target proteins involved in insulin secretion, gene transcription, and cellular metabolism
Exchange protein directly activated by cAMP (Epac1 and Epac2) – Regulates vesicle trafficking and exocytosis through mechanisms independent of PKA

The combined actions of PKA and Epac pathways coordinate the cellular responses that characterize GLP-1 receptor activation.

Pancreatic Effects: Glucose-Dependent Insulin Secretion

In pancreatic beta cells, lixisenatide-induced GLP-1 receptor activation produces glucose-dependent insulin secretion. This means that insulin release is amplified only when blood glucose levels are elevated, a safety feature that reduces hypoglycemia risk compared to insulin secretagogues like sulfonylureas, which stimulate insulin release regardless of glucose concentration.

The mechanism involves multiple steps:

cAMP-dependent closure of ATP-sensitive potassium channels, leading to beta cell membrane depolarization
Opening of voltage-gated calcium channels and calcium influx
Calcium-triggered fusion of insulin-containing granules with the cell membrane
Exocytosis of insulin into the bloodstream

Studies show that lixisenatide's effects on insulin secretion are most pronounced during the postprandial period, with relatively modest effects on fasting insulin levels. This reflects its short duration of action and timing of administration before the first meal.

Glucagon Suppression

Lixisenatide also activates GLP-1 receptors on pancreatic alpha cells, which produce glucagon. Glucagon is a counter-regulatory hormone that stimulates hepatic glucose production through glycogenolysis and gluconeogenesis. By suppressing inappropriate glucagon secretion during hyperglycemic states, lixisenatide reduces hepatic glucose output.

This glucagon suppression is also glucose-dependent: at low blood glucose concentrations, the counter-regulatory glucagon response remains intact, preserving the body's natural defenses against hypoglycemia. Clinical studies demonstrate that lixisenatide reduces postprandial glucagon concentrations without impairing the glucagon response to hypoglycemia.

Gastric Emptying: The Primary Mechanism

Perhaps the most distinctive feature of lixisenatide among GLP-1 agonists is its profound effect on gastric emptying. Multiple clinical studies have demonstrated that lixisenatide produces sustained and marked slowing of the rate at which food exits the stomach and enters the small intestine.

One randomized controlled trial found that after 8 weeks of lixisenatide treatment, the 50% gastric emptying time increased by an average of 211.5 minutes compared to a decrease of 24.1 minutes with placebo. Another study reported that gastric retention of a glucose drink was more than doubled (ratio of 2.19) with lixisenatide compared to placebo.

This gastric slowing has several important consequences:

Delayed glucose absorption – Slowing gastric emptying reduces the rate at which ingested carbohydrates are delivered to the small intestine, where they are absorbed into the bloodstream. This "time-release" effect blunts postprandial glucose spikes.
Reduced nutrient appearance rate – Studies using stable isotope tracers show that lixisenatide significantly reduces the rate of systemic appearance of oral glucose, directly correlating with the degree of gastric slowing.
Correlation with glucose lowering – Research has identified a strong inverse relationship (r = -0.74) between the magnitude of gastric slowing and postprandial glucose reduction, indicating that delayed gastric emptying is the primary mechanism through which lixisenatide controls postprandial hyperglycemia.

Importantly, this gastric slowing effect does not diminish with sustained treatment. Studies evaluating patients after 8 weeks of therapy found persistent gastric delay, distinguishing lixisenatide from some other short-acting GLP-1 agonists where gastric effects may attenuate over time.

Central Nervous System Effects

GLP-1 receptors are also expressed in multiple brain regions, including areas involved in appetite regulation such as the hypothalamus and brainstem. Activation of these receptors contributes to increased satiety and reduced food intake, mechanisms that likely contribute to the weight loss observed with lixisenatide treatment.

While lixisenatide demonstrates modest weight loss effects compared to longer-acting GLP-1 agonists like semaglutide and tirzepatide, patients in clinical trials typically experienced weight reductions ranging from 0.2 to 2.96 kg over 24 weeks of treatment.

Cardiovascular and Renal Effects

Beyond glycemic control, GLP-1 receptor activation produces effects on cardiovascular and renal physiology. While lixisenatide was not shown to reduce cardiovascular events in the ELIXA trial (discussed below), exploratory analyses suggested potential renal benefits, including reduced progression of albuminuria in patients with existing kidney disease.

Clinical Research and Evidence

Lixisenatide's clinical development program represents one of the most comprehensive evaluations of a GLP-1 receptor agonist, encompassing over 4,500 participants across multiple continents and diverse patient populations. The evidence base includes the 13-trial GetGoal program evaluating efficacy and safety, as well as the ELIXA cardiovascular outcomes trial mandated by regulatory authorities.

The GetGoal Clinical Trial Program

The GetGoal program was designed to assess lixisenatide's efficacy and safety across the spectrum of type 2 diabetes care—from newly diagnosed patients to those requiring intensive insulin therapy. The program's design allowed evaluation of lixisenatide as monotherapy, in combination with oral antidiabetic agents, and as an adjunct to basal insulin.

Efficacy Outcomes

Across the GetGoal trials, lixisenatide demonstrated consistent HbA1c reductions:

HbA1c reduction range: -0.46% to -1.0% depending on background therapy and baseline glycemic control
Postprandial glucose reductions: -3.1 to -7.96 mmol/L (55.8 to 143.3 mg/dL), with the most pronounced effects on the meal immediately following injection
Weight change: -0.2 to -2.96 kg over 24-week treatment periods

The magnitude of HbA1c lowering varied based on background therapy. When added to metformin, lixisenatide reduced HbA1c by 0.46%. When combined with a sulfonylurea, the reduction was 0.58%. When added to basal insulin (with or without metformin), the reduction was 0.36%.

These results position lixisenatide as a moderate-efficacy glucose-lowering agent. While the HbA1c reductions are clinically meaningful, they are generally smaller than those observed with longer-acting GLP-1 agonists like semaglutide (HbA1c reduction ~1.5-2.0%) or dual agonists like tirzepatide (HbA1c reduction ~2.0-2.5%).

GetGoal-X: Head-to-Head Comparison with Exenatide

One of the most informative trials in the GetGoal program was GetGoal-X, which directly compared lixisenatide to exenatide, the first-generation GLP-1 agonist. This 24-week, randomized, open-label study enrolled 634 patients with type 2 diabetes inadequately controlled on metformin.

Participants received either:

Lixisenatide 20 μg once daily (after 14-day initiation at 10 μg)
Exenatide 10 μg twice daily

Results:

Outcome	Lixisenatide	Exenatide	Difference
HbA1c reduction	-0.79% (7.97% → 7.17%)	-0.96% (7.96% → 7.01%)	0.17% (met noninferiority)
Weight loss	-3.8 kg	-3.8 kg	No significant difference
Symptomatic hypoglycemia	2.5%	7.9%	P < 0.05 (lixisenatide lower)
Nausea	24.5%	35.1%	P < 0.05 (lixisenatide lower)

The study demonstrated that lixisenatide was noninferior to twice-daily exenatide for HbA1c reduction, while offering potential advantages in tolerability. The once-daily dosing also represented a convenience benefit compared to exenatide's twice-daily regimen. These results supported lixisenatide's competitive positioning among short-acting GLP-1 agonists, though both have since been largely superseded by once-weekly formulations.

GetGoal-O: Efficacy in Older Patients

GetGoal-O specifically evaluated lixisenatide in older adults (≥70 years) with type 2 diabetes, a population often underrepresented in diabetes trials. The study demonstrated that lixisenatide maintained efficacy in this age group while showing a safety profile consistent with younger populations, supporting its use across the adult age spectrum.

The ELIXA Trial: Cardiovascular Outcomes

The Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) was a pivotal cardiovascular outcomes trial mandated by the FDA and EMA following concerns about cardiovascular safety signals with early incretin-based therapies.

Study Design

ELIXA was a multinational, randomized, double-blind, placebo-controlled trial that enrolled 6,068 patients with type 2 diabetes who had experienced a recent acute coronary syndrome (myocardial infarction or unstable angina requiring hospitalization) within the preceding 180 days. Patients were randomized 1:1 to receive:

Lixisenatide 20 μg once daily (after dose escalation)
Placebo

Both groups received standard care for diabetes and cardiovascular disease according to local guidelines. The median follow-up duration was 25 months, with enrollment occurring between 2010 and 2013 across 49 countries.

Primary Outcome: Major Adverse Cardiovascular Events (MACE)

The primary endpoint was a composite of:

Cardiovascular death
Nonfatal myocardial infarction
Nonfatal stroke
Hospitalization for unstable angina

Results:

The primary outcome occurred in:

13.4% of patients in the lixisenatide group
13.2% of patients in the placebo group

Hazard ratio: 1.02 (95% CI: 0.89-1.17)

P for noninferiority < 0.001 (noninferiority established)
P for superiority = 0.81 (no cardiovascular benefit)

These findings demonstrated that lixisenatide was cardiovascularly safe in a high-risk population, meeting the regulatory requirement to rule out excess cardiovascular risk. However, unlike liraglutide (LEADER trial) and semaglutide (SUSTAIN-6 trial), lixisenatide did not demonstrate cardiovascular benefit.

The neutral cardiovascular result distinguishes lixisenatide from some other GLP-1 agonists and may reflect differences in mechanisms of action, duration of receptor activation, or effects on cardiovascular risk factors beyond glucose control. The finding was published in the New England Journal of Medicine in 2015 and influenced clinical practice guidelines regarding GLP-1 agonist selection for patients with established cardiovascular disease.

Secondary Findings: Renal Outcomes

An exploratory post-hoc analysis of ELIXA data examined effects on renal function. Published in The Lancet Diabetes & Endocrinology in 2018, this analysis found that lixisenatide:

Reduced progression of albuminuria in patients with macroalbuminuria at baseline
Lowered the risk of new-onset macroalbuminuria compared to placebo
Showed trends toward renal protection that warranted further investigation

While these findings were exploratory and hypothesis-generating, they aligned with mounting evidence that GLP-1 receptor agonists may confer renal benefits beyond glycemic control.

Clinical Trial Summary

The comprehensive clinical evidence for lixisenatide demonstrates:

✓ Consistent glucose lowering across diverse patient populations ✓ Particular efficacy for postprandial glucose control ✓ Cardiovascular safety in high-risk patients ✓ Favorable tolerability compared to twice-daily exenatide ✓ Potential renal benefits requiring confirmation in dedicated trials

However, the moderate magnitude of HbA1c reduction, lack of cardiovascular benefit, and once-daily injection requirement positioned lixisenatide at a competitive disadvantage compared to newer agents offering greater efficacy, cardiovascular risk reduction, or once-weekly dosing convenience.

Administration and Dosing

Lixisenatide was designed as a once-daily subcutaneous injection administered within one hour before the first meal of the day. This prandial timing is critical to maximizing the drug's primary mechanism—gastric slowing and postprandial glucose control.

Dosing Regimen

Initiation Phase (Days 1-14):

10 μg once daily subcutaneously

Maintenance Phase (Day 15 onward):

20 μg once daily subcutaneously

The two-week initiation period at the lower dose was designed to improve gastrointestinal tolerability, as nausea and vomiting are common side effects during GLP-1 agonist therapy initiation. Starting at half the maintenance dose allows gradual adaptation to the drug's gastric effects.

Injection Technique and Sites

Lixisenatide was supplied in prefilled pen injectors:

Green pen (starter pack): Contains 10 μg doses
Burgundy pen (maintenance pack): Contains 20 μg doses

Approved injection sites:

Abdomen
Thigh
Upper arm

Patients were instructed to rotate injection sites within the same body region to reduce the risk of lipodystrophy (changes in subcutaneous fat at injection sites). The injection should be given subcutaneously (into the fatty tissue layer beneath the skin), not intramuscularly or intravenously.

Pharmacokinetic studies demonstrated no clinically significant differences in absorption between injection sites, allowing flexibility in site selection based on patient preference.

Timing Considerations

The requirement to inject lixisenatide within one hour before the first meal reflected its short-acting pharmacokinetic profile and primary mechanism of gastric slowing. Administering the injection before eating ensures that:

Peak drug concentrations coincide with meal ingestion
Gastric emptying is maximally delayed during the period of nutrient intake
Postprandial glucose excursions are optimally controlled

Studies confirmed that lixisenatide's effects were most pronounced on the meal immediately following injection, with diminishing effects on subsequent meals throughout the day. This differs from long-acting GLP-1 agonists like semaglutide and dulaglutide, which can be administered at any time of day regardless of meals due to their sustained receptor activation.

Dose Adjustments

Renal Impairment: No dose adjustment was required for patients with mild, moderate, or severe renal impairment. Lixisenatide was eliminated through glomerular filtration and proteolytic degradation, with a mean apparent clearance of approximately 35 L/h. However, no clinical studies evaluated lixisenatide in patients with end-stage renal disease requiring dialysis.

Hepatic Impairment: No dose adjustment was required for patients with hepatic impairment, as the liver plays a minimal role in lixisenatide elimination.

Elderly Patients: No dose adjustment was needed based solely on age, as demonstrated in the GetGoal-O trial evaluating patients ≥70 years.

Missed Doses

If a dose was missed, patients were instructed to administer it within one hour before the next meal. If this window passed, the missed dose should be skipped, and the regular schedule resumed the following day. Doubling up on doses to compensate for a missed injection was explicitly discouraged due to increased risk of gastrointestinal side effects.

Storage and Handling

Unopened pens: Store refrigerated at 2-8°C (36-46°F)
In-use pens: May be stored at room temperature (below 30°C/86°F) for up to 14 days
Protection: Keep pens away from direct heat and light
Disposal: Used pens should be disposed of in accordance with local regulations for sharps/medical waste

Safety Profile and Side Effects

Lixisenatide's safety profile was extensively characterized through the GetGoal clinical trial program and ELIXA cardiovascular outcomes trial, providing data on over 10,000 patient-years of exposure. The safety profile aligns with the GLP-1 receptor agonist class, with gastrointestinal effects representing the most common adverse events.

Common Adverse Events

Gastrointestinal Effects

The most frequently reported side effects were related to the gastrointestinal system, reflecting GLP-1 receptor activation in the gut:

Adverse Event	Incidence
Nausea	25%
Vomiting	10%
Diarrhea	5-10%
Constipation	3-5%
Abdominal pain	3-5%

These effects were most prominent during treatment initiation and typically diminished over 2-4 weeks as tolerance developed. The 14-day dose escalation period (starting at 10 μg before advancing to the 20 μg maintenance dose) was specifically designed to mitigate these symptoms.

In the GetGoal-X head-to-head trial, lixisenatide showed significantly lower rates of nausea (24.5%) compared to twice-daily exenatide (35.1%, P < 0.05), suggesting a potential tolerability advantage over at least one other short-acting GLP-1 agonist.

The gastrointestinal effects result from:

Delayed gastric emptying (the drug's primary mechanism)
Direct activation of GLP-1 receptors in the enteric nervous system
Altered intestinal motility patterns

Patients experiencing persistent or severe gastrointestinal symptoms were advised to contact their healthcare provider, as these could indicate complications or the need for dose adjustment or treatment discontinuation.

Hypoglycemia

As a glucose-dependent insulinotropic agent, lixisenatide carries a low intrinsic risk of hypoglycemia when used alone. However, hypoglycemia risk increases when combined with insulin or insulin secretagogues (sulfonylureas or meglitinides).

GetGoal-X findings:

Symptomatic hypoglycemia with lixisenatide monotherapy: 2.5%
Symptomatic hypoglycemia with exenatide: 7.9% (P < 0.05)

When lixisenatide was added to basal insulin therapy (GetGoal-L and GetGoal-L-Asia trials), hypoglycemia rates increased, necessitating reductions in insulin doses. Clinical practice guidelines recommended reducing basal insulin doses by 10-20% when initiating lixisenatide in insulin-treated patients.

Sulfonylurea doses also required consideration when adding lixisenatide, with potential need for dose reduction to minimize hypoglycemia risk.

Injection Site Reactions

Local injection site reactions occurred in approximately 2-5% of patients and typically consisted of:

Mild erythema (redness)
Pruritus (itching)
Localized swelling

These reactions were generally self-limited and resolved without intervention. Rotating injection sites reduced the frequency and severity of these events.

Pancreatitis Concerns

As with all GLP-1 receptor agonists, lixisenatide carried a black box warning regarding potential pancreatitis risk. Post-marketing surveillance and clinical trial data suggested rare cases of acute pancreatitis in patients receiving lixisenatide.

Clinical recommendations:

Patients should be informed about pancreatitis symptoms (severe, persistent abdominal pain radiating to the back, often accompanied by vomiting)
Lixisenatide should be discontinued if pancreatitis is suspected
The drug should not be restarted if pancreatitis is confirmed
Consider alternative therapies in patients with a history of pancreatitis

The causal relationship between GLP-1 agonists and pancreatitis remains debated in the medical literature, as patients with type 2 diabetes have elevated baseline pancreatitis risk due to obesity, hypertriglyceridemia, and other metabolic factors. Large observational studies and meta-analyses have not demonstrated a clear causal link, but the signal warranted cautious monitoring.

Renal Function Considerations

Cases of acute kidney injury and worsening chronic kidney disease were reported in patients receiving lixisenatide, particularly in the setting of:

Volume depletion from severe gastrointestinal side effects (vomiting, diarrhea)
Dehydration
Concurrent use of medications affecting renal function (NSAIDs, ACE inhibitors, diuretics)

Patients were advised to maintain adequate hydration, especially during treatment initiation. Healthcare providers monitored renal function in at-risk patients, particularly those with pre-existing kidney disease or risk factors for acute kidney injury.

Thyroid C-Cell Tumors (Black Box Warning)

Like all GLP-1 receptor agonists, lixisenatide carried a black box warning based on rodent studies showing increased incidence of thyroid C-cell tumors (medullary thyroid carcinoma) at clinically relevant doses.

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC)
Multiple endocrine neoplasia syndrome type 2 (MEN 2)

The clinical relevance of rodent thyroid findings to humans remains uncertain, as human thyroid C-cells express markedly lower levels of GLP-1 receptors compared to rodents. Post-marketing surveillance has not identified increased MTC incidence in humans, but the warning remained in place due to the severity of the potential risk.

Immunogenicity

As a peptide drug, lixisenatide has the potential to induce anti-drug antibodies. In clinical trials:

Approximately 70% of patients developed antibodies to lixisenatide
Most antibody responses were low-titer and did not affect efficacy
High-titer antibodies (occurred in ~2-4% of patients) were occasionally associated with reduced glycemic efficacy

Routine antibody testing was not recommended in clinical practice, but lack of efficacy despite appropriate dosing and adherence could prompt consideration of antibody-mediated resistance.

Cardiovascular Safety

The ELIXA trial definitively established that lixisenatide does not increase cardiovascular risk in patients with type 2 diabetes and recent acute coronary syndrome—a high-risk population. The hazard ratio of 1.02 (95% CI: 0.89-1.17) for major adverse cardiovascular events demonstrates neither harm nor benefit.

This neutral cardiovascular profile differs from liraglutide and semaglutide, which demonstrated cardiovascular benefits in their respective outcomes trials. The reasons for these differences may relate to duration of GLP-1 receptor activation, effects on cardiovascular risk factors, or other mechanisms.

Drug Interactions

Oral medications with narrow therapeutic index or requiring rapid onset: Lixisenatide's marked effect on gastric emptying can delay the absorption of orally administered medications. This is particularly relevant for:

Oral contraceptives
Antibiotics requiring specific timing
Analgesics needed for acute pain relief

Clinical guidance recommended administering such medications at least 1 hour before or 4 hours after lixisenatide injection to minimize interaction risks.

Legal and Regulatory Status

FDA Approval and U.S. Market Withdrawal

Lixisenatide received FDA approval on July 27, 2016, for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The approval was based on the comprehensive GetGoal clinical trial program demonstrating efficacy and the ELIXA trial establishing cardiovascular safety.

The drug was marketed in the United States under the brand name Adlyxin by Sanofi.

However, on October 20, 2022, Sanofi announced that it would discontinue sales of Adlyxin in the United States, with the drug becoming unavailable as of January 1, 2023. The company cited business reasons for this decision, including:

Market competition from newer GLP-1 agonists with more convenient dosing (once-weekly options like semaglutide and dulaglutide)
Availability of alternative treatments offering greater efficacy or cardiovascular benefits
Overall commercial performance and strategic portfolio priorities

The withdrawal was a business decision rather than a safety concern. Patients using Adlyxin in the U.S. were transitioned to alternative GLP-1 receptor agonists or other diabetes therapies under medical supervision.

International Availability

European Union: Lixisenatide was approved by the European Medicines Agency (EMA) in 2013 under the brand name Lyxumia. It remains available in European markets as of 2024.

Japan: The drug is approved and available in Japan, with post-marketing surveillance studies (such as the PRANDIAL study) demonstrating durability of safety and effectiveness in real-world Japanese populations with type 2 diabetes.

Other Markets: Lixisenatide has received regulatory approval in numerous countries worldwide and remains commercially available in many regions outside the United States.

Prescription Status and DEA Scheduling

Lixisenatide is a prescription-only medication requiring authorization from a licensed healthcare provider. It is not a controlled substance and does not appear on DEA scheduling lists, as it lacks abuse potential.

Research Use and Investigational Status

While lixisenatide's commercial trajectory in the U.S. has ended, the peptide continues to be studied in research contexts:

Neurological Research: Lixisenatide is being investigated for potential neuroprotective effects in Parkinson's disease. A Phase 2 trial published in The New England Journal of Medicine (2023) showed that lixisenatide significantly slowed motor progression in early Parkinson's disease compared to placebo over 12 months. The mechanisms underlying this effect likely involve GLP-1 receptor activation in the brain, promoting neuronal survival and reducing neuroinflammation. This represents a potential repurposing opportunity for lixisenatide beyond its original type 2 diabetes indication.

Combination Therapies: Sanofi previously developed and marketed iGlarLixi (brand name Soliqua in the U.S., Suliqua in Europe)—a fixed-ratio combination of insulin glargine (basal insulin) and lixisenatide. This product simplified treatment for patients requiring both basal insulin and a GLP-1 agonist by delivering both medications in a single daily injection. Following discontinuation of standalone lixisenatide in the U.S., the status of iGlarLixi became uncertain, though it remained available in some markets.

Legal Considerations for Gray Market Sourcing

With the discontinuation of Adlyxin in the U.S., patients and researchers should be aware of legal issues surrounding alternative sourcing:

Research Peptide Suppliers: Lixisenatide may be available from research chemical suppliers marketing peptides "for research purposes only." These sources operate in a regulatory gray area:

Products are not FDA-approved for human use
Quality, purity, and sterility are not guaranteed
Using such products for human administration violates FDA regulations
No medical oversight or quality control exists

International Pharmacies: Importing lixisenatide from countries where it remains available (e.g., European pharmacies) carries legal risks:

FDA regulations generally prohibit importation of unapproved drugs
Exceptions exist for personal importation under specific circumstances, but enforcement varies
Insurance coverage is not available for internationally sourced medications
Authenticity and quality cannot be verified

Clinical Recommendations: Healthcare providers and patients should explore FDA-approved alternatives within the GLP-1 receptor agonist class rather than pursuing gray market sourcing. Options include liraglutide, semaglutide, dulaglutide, and exenatide, all of which remain available through legitimate channels with appropriate medical oversight.

Frequently Asked Questions

How does lixisenatide compare to semaglutide?

Lixisenatide and semaglutide are both GLP-1 receptor agonists but differ substantially in their pharmacokinetic profiles, efficacy, and clinical effects.

Duration of Action:

Lixisenatide: Short-acting (half-life ~3 hours), administered once daily
Semaglutide: Long-acting (half-life ~7 days), administered once weekly

Mechanism Emphasis:

Lixisenatide: Primary effect through gastric slowing, targeting postprandial glucose
Semaglutide: Balanced effects on fasting and postprandial glucose through sustained receptor activation

Efficacy:

Lixisenatide: HbA1c reduction of 0.5-1.0%, weight loss of 0.2-3 kg
Semaglutide: HbA1c reduction of 1.5-2.0%, weight loss of 5-15 kg (dose-dependent)

Cardiovascular Outcomes:

Lixisenatide: Neutral (ELIXA trial: no increase or decrease in cardiovascular events)
Semaglutide: Beneficial (SUSTAIN-6 trial: 26% reduction in major adverse cardiovascular events)

Availability:

Lixisenatide: Discontinued in the U.S. as of 2023; available in Europe and other markets
Semaglutide: Widely available in the U.S. and globally (Ozempic for diabetes, Wegovy for weight management)

For patients seeking GLP-1 therapy with cardiovascular benefits and greater efficacy, semaglutide represents a superior option. Lixisenatide's advantages—once-daily dosing and particular efficacy for postprandial control—are now largely academic given its U.S. market withdrawal.

Can lixisenatide be used for weight loss?

Lixisenatide was FDA-approved specifically for type 2 diabetes management, not for weight loss in individuals without diabetes. While patients in clinical trials did experience modest weight loss (typically 0.2-3 kg over 24 weeks), the magnitude of weight reduction was substantially smaller than that observed with weight-loss-specific GLP-1 formulations.

Comparison to weight loss agents:

Lixisenatide: ~0.5-3 kg (1-6.6 lbs) weight loss in diabetes trials
Semaglutide 2.4 mg (Wegovy): ~15 kg (33 lbs) weight loss in obesity trials
Tirzepatide 15 mg (Zepbound): ~22 kg (48 lbs) weight loss in obesity trials

The more modest weight loss with lixisenatide likely reflects its short-acting profile, which produces less sustained appetite suppression compared to long-acting agents. With lixisenatide's discontinuation in the U.S. market, it is no longer a practical option for weight management purposes. Patients seeking GLP-1-based weight loss therapy should consider FDA-approved options like semaglutide (Wegovy) or tirzepatide (Zepbound).

What is the difference between lixisenatide and exenatide?

Both peptides are structurally derived from exendin-4, but lixisenatide incorporates modifications that alter its pharmacological properties:

Structural Differences:

Exenatide: 39 amino acids; synthetic version of native exendin-4
Lixisenatide: 44 amino acids; deletion of proline-38 plus addition of six C-terminal lysine residues

Receptor Binding:

Lixisenatide: ~2.5-fold greater GLP-1 receptor binding affinity than exenatide

Dosing:

Exenatide (immediate-release): 5-10 μg twice daily
Lixisenatide: 10-20 μg once daily
Exenatide (extended-release, Bydureon): 2 mg once weekly

Efficacy (GetGoal-X head-to-head trial):

HbA1c reduction: Lixisenatide -0.79%, exenatide -0.96% (noninferior)
Weight loss: Similar between both agents (~3.8 kg)
Hypoglycemia: Lower with lixisenatide (2.5% vs 7.9%)
Nausea: Lower with lixisenatide (24.5% vs 35.1%)

The once-daily dosing of lixisenatide offered a convenience advantage over twice-daily exenatide, with modestly better gastrointestinal tolerability. However, once-weekly exenatide (Bydureon/Bydureon BCise) provided even greater dosing convenience, and both lixisenatide and twice-daily exenatide have now been largely supplanted by newer agents.

Why was Adlyxin discontinued in the United States?

Sanofi's decision to discontinue Adlyxin (lixisenatide) in the U.S. was business-driven rather than safety-related. Several factors likely contributed:

Market Competition: The GLP-1 agonist market became increasingly competitive after lixisenatide's 2016 approval, with the emergence of once-weekly options:

Semaglutide (Ozempic) approved in 2017
Dulaglutide (Trulicity) gaining market share
Once-weekly dosing offered significant convenience advantages over daily injections

Efficacy Profile: Lixisenatide's moderate HbA1c reduction (0.5-1.0%) and modest weight loss effects positioned it at a disadvantage compared to:

Semaglutide's superior glucose lowering (1.5-2.0% HbA1c reduction)
Cardiovascular benefits demonstrated by liraglutide and semaglutide (which lixisenatide lacked)
Greater weight loss with newer agents

Commercial Performance: Adlyxin never achieved significant market penetration in the highly competitive U.S. diabetes market. Physician and patient preferences shifted toward agents offering:

Less frequent dosing
Greater efficacy
Cardiovascular risk reduction
More substantial weight loss

Strategic Portfolio Decisions: Pharmaceutical companies regularly reassess product portfolios based on commercial viability and strategic priorities. Sanofi likely concluded that resources devoted to Adlyxin would generate better returns if redirected to other products.

The discontinuation does not reflect safety concerns—lixisenatide remains available and in use in European and Asian markets where commercial dynamics differ.

Is lixisenatide effective for postprandial glucose control?

Yes, lixisenatide is particularly effective for postprandial (after-meal) glucose control, which is its primary clinical differentiation within the GLP-1 agonist class. This effect stems from its pronounced impact on gastric emptying.

Clinical Evidence: Studies demonstrated that lixisenatide:

Increased gastric emptying time by >200 minutes compared to baseline
Reduced 2-hour postprandial glucose by 3.1-7.96 mmol/L (55.8-143.3 mg/dL)
Showed a strong correlation (r = -0.74) between gastric slowing magnitude and glucose reduction

Mechanism: By markedly delaying the rate at which food exits the stomach and enters the small intestine, lixisenatide creates a "time-release" effect for ingested carbohydrates. This blunts the rapid glucose spikes that occur in the 1-3 hours following meals—periods when glucose excursions are often most difficult to control.

Comparison to Long-Acting GLP-1 Agonists: While long-acting agents like semaglutide and liraglutide also slow gastric emptying initially, tolerance to this effect can develop over weeks to months. Lixisenatide's effects on gastric emptying remained sustained even after 8 weeks of continuous treatment, suggesting less tachyphylaxis to the gastric slowing effect.

Clinical Context: The pronounced postprandial effect made lixisenatide particularly well-suited for patients with:

Primarily postprandial hyperglycemia despite controlled fasting glucose
Basal insulin therapy providing adequate fasting control but inadequate postprandial coverage

This rationale led to the development of iGlarLixi (Soliqua/Suliqua)—a fixed-ratio combination of insulin glargine and lixisenatide designed to address both fasting (via basal insulin) and postprandial (via lixisenatide) glucose excursions in a single injection.

What are alternatives to lixisenatide?

For patients previously using lixisenatide or considering GLP-1 agonist therapy, several FDA-approved alternatives remain available:

Short-Acting GLP-1 Agonists:

Exenatide immediate-release (Byetta): 5-10 μg twice daily; similar prandial approach but less convenient dosing

Long-Acting GLP-1 Agonists (once-weekly):

Semaglutide (Ozempic): Most prescribed GLP-1 agonist; superior efficacy (HbA1c reduction ~1.5-2.0%, weight loss ~5-15 kg); cardiovascular benefits; once-weekly dosing
Dulaglutide (Trulicity): Once-weekly; good efficacy; cardiovascular benefits; auto-injector device
Exenatide extended-release (Bydureon BCise): Once-weekly formulation of exenatide; microsphere suspension technology

Long-Acting GLP-1 Agonists (daily):

Liraglutide (Victoza): Once-daily; established cardiovascular benefits (LEADER trial); HbA1c reduction ~1.0-1.5%

Dual GIP/GLP-1 Agonists:

Tirzepatide (Mounjaro): Once-weekly; activates both GLP-1 and GIP receptors; superior efficacy (HbA1c reduction ~2.0-2.5%, weight loss up to 22 kg); newest option with greatest efficacy

Combination Products:

Insulin degludec/liraglutide (Xultophy): Combines basal insulin with GLP-1 agonist
Insulin glargine/lixisenatide (Soliqua/Suliqua): Combines basal insulin with lixisenatide (availability uncertain following Adlyxin discontinuation)

Selection Considerations:

Dosing convenience: Once-weekly agents (semaglutide, dulaglutide, tirzepatide) offer the most convenient regimens
Cardiovascular disease: Semaglutide, liraglutide, and dulaglutide have demonstrated cardiovascular benefits
Weight loss priority: Semaglutide and tirzepatide offer the greatest weight reduction
Postprandial control: Short-acting agents like exenatide may provide more pronounced postprandial effects, though less than lixisenatide
Renal function: Most GLP-1 agonists require no renal dose adjustment, but specific considerations exist for severe kidney disease

Transition decisions should be made in consultation with a healthcare provider who can consider individual patient factors, comorbidities, treatment goals, and insurance coverage.

Can lixisenatide cause pancreatitis?

Lixisenatide, like all GLP-1 receptor agonists, carries a warning regarding potential pancreatitis risk. However, the causal relationship remains a subject of scientific debate and ongoing investigation.

Clinical Trial Data: In the GetGoal program and ELIXA trial, cases of acute pancreatitis occurred rarely:

Rates were generally low (<0.5% in most trials)
Incidence was similar between lixisenatide and placebo groups in ELIXA
No clear dose-response relationship was established

Mechanism Uncertainty: The biological plausibility of GLP-1 agonists causing pancreatitis is unclear:

GLP-1 receptors are expressed on pancreatic ductal cells and may theoretically affect exocrine function
Animal studies have shown mixed results, with some suggesting pancreatic inflammation and others showing no effect
Human pancreatic tissue studies have not definitively demonstrated harmful effects

Confounding Factors: Patients with type 2 diabetes have elevated baseline pancreatitis risk due to:

Obesity (a major independent pancreatitis risk factor)
Hypertriglyceridemia (triglyceride levels >500 mg/dL substantially increase pancreatitis risk)
Gallstones (more common in diabetes and obesity)
Alcohol use
Certain medications (e.g., thiazide diuretics, azathioprine)

Large-Scale Evidence: Multiple large observational studies and meta-analyses examining tens of thousands of patients have not demonstrated a clear causal link between GLP-1 agonists and pancreatitis. A 2017 meta-analysis of cardiovascular outcomes trials (including ELIXA) found no significant increase in pancreatitis risk with GLP-1 agonists compared to placebo.

Clinical Recommendations: Despite the uncertain causality, regulatory agencies and clinical guidelines recommend:

Patient education: Inform patients about pancreatitis symptoms (severe, persistent abdominal pain radiating to the back, often with vomiting)
Prompt evaluation: Discontinue lixisenatide and evaluate for pancreatitis if symptoms develop
Avoid in high-risk patients: Consider alternative therapies for patients with a history of pancreatitis
Do not restart if confirmed: If pancreatitis is diagnosed, do not reinitiate lixisenatide

Bottom Line: While a theoretical risk exists and warnings remain in place, current evidence does not establish that lixisenatide or other GLP-1 agonists directly cause pancreatitis in most patients. The benefit-risk profile remains favorable for the vast majority of patients, but vigilance for symptoms and appropriate patient selection remain important.

Is lixisenatide being studied for Parkinson's disease?

Yes, lixisenatide has emerged as a promising investigational therapy for Parkinson's disease, representing a potential therapeutic repurposing beyond its original diabetes indication.

Mechanism Rationale: GLP-1 receptors are expressed in multiple brain regions, including the substantia nigra (the area affected by dopaminergic neuron loss in Parkinson's disease). Preclinical studies suggest that GLP-1 receptor activation may provide neuroprotective effects through several mechanisms:

Reducing oxidative stress and neuroinflammation
Promoting neuronal survival and mitochondrial function
Enhancing neurotrophic factor expression
Improving insulin signaling in the brain (which may be impaired in neurodegenerative diseases)

Clinical Evidence: A Phase 2 randomized, double-blind, placebo-controlled trial published in The New England Journal of Medicine in 2023 evaluated lixisenatide in patients with early Parkinson's disease:

Study Design: 156 participants with Parkinson's disease (diagnosed within 3 years) were randomized to receive either lixisenatide 20 μg once daily or placebo for 12 months
Primary Outcome: Change in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III motor score from baseline to 12 months
Results: Lixisenatide significantly slowed motor progression compared to placebo. At 12 months, motor scores worsened by 0.04 points in the lixisenatide group versus 3.04 points in the placebo group (difference: 3.08 points; P < 0.001)
Safety: The drug was generally well tolerated, with gastrointestinal side effects (nausea) being the most common

Interpretation: These findings suggest that lixisenatide may modify disease progression in Parkinson's disease, not merely provide symptomatic relief. If confirmed in larger Phase 3 trials, this would represent a significant advance, as current Parkinson's therapies primarily address symptoms without altering underlying disease progression.

Comparison to Other GLP-1 Agonists: Exenatide and liraglutide have also been studied in Parkinson's disease with encouraging early signals, raising the possibility that neuroprotective effects may be a class effect of GLP-1 agonists rather than unique to lixisenatide.

Future Directions: Larger, longer-duration trials are needed to:

Confirm disease-modifying effects
Determine optimal dosing and treatment duration
Assess long-term safety in Parkinson's populations
Compare different GLP-1 agonists for neuroprotective efficacy

This research exemplifies how peptide therapeutics initially developed for metabolic diseases may find applications in neurodegenerative conditions, highlighting the versatility of GLP-1 receptor pharmacology.

The Bottom Line

Lixisenatide represents a distinctive member of the GLP-1 receptor agonist family, characterized by short-acting pharmacokinetics, pronounced gastric slowing effects, and particular efficacy for postprandial glucose control. As a synthetic analog of exendin-4 with enhanced receptor binding affinity, lixisenatide demonstrated consistent glucose-lowering efficacy across a comprehensive clinical development program involving over 4,500 participants.

The GetGoal trial program established that lixisenatide reduces HbA1c by 0.5-1.0% across diverse patient populations and background therapies, with especially marked effects on the glucose excursions following meals. This postprandial focus, mediated primarily through sustained gastric slowing, differentiated lixisenatide from long-acting GLP-1 agonists that emphasize 24-hour receptor activation. Head-to-head comparison with twice-daily exenatide demonstrated comparable efficacy with superior gastrointestinal tolerability and the convenience of once-daily dosing.

The ELIXA cardiovascular outcomes trial definitively established lixisenatide's safety in high-risk patients with type 2 diabetes and recent acute coronary syndrome, meeting regulatory requirements to rule out cardiovascular harm. However, unlike semaglutide and liraglutide, lixisenatide did not demonstrate cardiovascular benefit—a distinction that influenced treatment guidelines and clinical decision-making.

Despite FDA approval in 2016 and a well-characterized safety profile, lixisenatide faced intense market competition from agents offering greater efficacy, once-weekly dosing convenience, and cardiovascular risk reduction. These factors led to Sanofi's business decision to voluntarily withdraw Adlyxin from the U.S. market in January 2023, though the drug remains available in Europe, Japan, and other regions.

For patients and clinicians, lixisenatide's story illustrates both the sophisticated understanding of GLP-1 receptor pharmacology achieved over the past two decades and the competitive pressures that shape which scientific innovations succeed commercially. The peptide's profound effects on gastric emptying and postprandial glucose contributed meaningfully to diabetes pharmacotherapy, particularly when combined with basal insulin in products like iGlarLixi.

Looking forward, lixisenatide's investigation as a potential disease-modifying therapy for Parkinson's disease represents an intriguing second chapter. Early Phase 2 evidence suggesting neuroprotective effects opens possibilities for therapeutic repurposing that extend far beyond the peptide's original metabolic indications. Whether this research translates to approved neurological applications remains to be determined through ongoing trials.

For individuals seeking GLP-1 agonist therapy today, lixisenatide's U.S. discontinuation makes alternatives like semaglutide, tirzepatide, dulaglutide, and liraglutide the practical choices. These agents offer comparable or superior efficacy, more convenient dosing, and in some cases, cardiovascular benefits that extend beyond glucose control. Treatment decisions should be made in consultation with healthcare providers who can assess individual patient factors, treatment goals, comorbidities, and insurance coverage.

Lixisenatide's clinical development advanced understanding of postprandial glucose regulation and gastric emptying's role in GLP-1 agonist pharmacology. While the drug's commercial trajectory in the U.S. has concluded, its contributions to diabetes therapeutics and potential future applications in neurodegeneration ensure its place in the ongoing evolution of peptide-based medicine.

This article is for educational purposes only. PeptideJournal.org does not sell peptides, provide medical advice, or recommend the use of any unapproved substances. Always consult a qualified healthcare provider before making decisions about your health.

References

Rosenstock J, Raccah D, Korányi L, et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care. 2013;36(10):2945-2951. https://pubmed.ncbi.nlm.nih.gov/23698396/
Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247-2257. https://www.nejm.org/doi/full/10.1056/NEJMoa1509225
Meier JJ, Rosenstock J, Hincelin-Méry A, et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: A randomized, open-label trial. Diabetes Care. 2015;38(7):1263-1273. https://pubmed.ncbi.nlm.nih.gov/25887359/
Horowitz M, Aroda VR, Han J, et al. Effects of sustained treatment with lixisenatide on gastric emptying and postprandial glucose metabolism in type 2 diabetes: A randomized controlled trial. Diabetes Care. 2020;43(8):1813-1820. https://pubmed.ncbi.nlm.nih.gov/32471908/
Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care. 2012;35(6):1225-1231. https://pubmed.ncbi.nlm.nih.gov/22432104/
Ratner RE, Rosenstock J, Boka G; DRI6012 Study Investigators. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med. 2010;27(9):1024-1032. https://pubmed.ncbi.nlm.nih.gov/20722676/
Bolli GB, Munteanu M, Dotsenko S, et al. Efficacy and safety of lixisenatide once daily vs. placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabet Med. 2014;31(2):176-184. https://pubmed.ncbi.nlm.nih.gov/24111982/
Riddle MC, Forst T, Aronson R, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care. 2013;36(9):2497-2503. https://pubmed.ncbi.nlm.nih.gov/23564921/
Ahren B, Leguizamo Dimas A, Miossec P, Saubadu S, Aronson R. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care. 2013;36(9):2543-2550. https://pubmed.ncbi.nlm.nih.gov/23645884/
Umpierrez G, Tofe Povedano S, Pérez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37(8):2168-2176. https://pubmed.ncbi.nlm.nih.gov/24842985/
Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39-47. https://pubmed.ncbi.nlm.nih.gov/19515413/
Werner U, Haschke G, Herling AW, Kramer W. Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept. 2010;164(2-3):58-64. https://pubmed.ncbi.nlm.nih.gov/20570596/
Lorenz M, Evers A, Wagner M. Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity. Bioorg Med Chem Lett. 2013;23(14):4011-4018. https://pubmed.ncbi.nlm.nih.gov/23756079/
Kapitza C, Forst T, Coester HV, Poitiers F, Ruus P, Hincelin-Méry A. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab. 2013;15(7):642-649. https://pubmed.ncbi.nlm.nih.gov/23368662/
Rosenstock J, Guerci B, Hanefeld M, et al. Prandial options to advance basal insulin glargine therapy: Testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 diabetes: The GetGoal Duo-2 Trial. Diabetes Care. 2016;39(8):1318-1328. https://pubmed.ncbi.nlm.nih.gov/27222505/
Berria R, Manghi FP, Blicher TM, et al. Efficacy and safety of lixisenatide therapy in older patients with type 2 diabetes inadequately controlled on their current antidiabetic treatment: The GetGoal-O randomized trial. Diabetes Care. 2017;40(4):485-493. https://pubmed.ncbi.nlm.nih.gov/28254876/
Pinget M, Goldenberg R, Niemoeller E, Muehlen-Bartmer I, Guo H, Aronson R. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes Obes Metab. 2013;15(11):1000-1007. https://pubmed.ncbi.nlm.nih.gov/23679879/
Seino Y, Min KW, Niemoeller E, Takami A; EFC10887 GETGOAL-L Asia Study Investigators. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab. 2012;14(10):910-917. https://pubmed.ncbi.nlm.nih.gov/22564826/
Meneilly GS, Roy-Duval C, Alawi H, et al. Lixisenatide therapy in older patients with type 2 diabetes inadequately controlled on their current antidiabetic treatment: the GetGoal-O randomized trial. Diabetes Care. 2017;40(4):485-493. https://pubmed.ncbi.nlm.nih.gov/28254876/
Lorenz M, Evers A, Wagner M. Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity. Bioorg Med Chem Lett. 2013;23(14):4011-4018. https://pubmed.ncbi.nlm.nih.gov/23756079/
Hutchison AL, Rosenstock J. Lixisenatide (Adlyxin): The newest addition to the GLP-1 agonist class. Pharm Ther. 2017;42(10):640-643. PMC5642155
Raccah D, Miossec P, Esposito V, Niemoeller E, Cho M, Gerich J. Efficacy and safety of lixisenatide in elderly (≥65 years old) and very elderly (≥75 years old) patients with type 2 diabetes: An analysis from the GetGoal phase III programme. Diabetes Metab Res Rev. 2015;31(2):204-211. https://pubmed.ncbi.nlm.nih.gov/25088265/
Cariou B, Fontaine P, Eschwege E, et al. Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: Results from the DIALOG study. Diabetes Metab. 2015;41(2):116-125. https://pubmed.ncbi.nlm.nih.gov/25623474/
Perkovic V, Toto R, Cooper ME, et al. Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: secondary analysis of the CARMELINA randomized trial. Diabetes Care. 2020;43(8):1803-1812. https://pubmed.ncbi.nlm.nih.gov/32471905/
Mann JFE, Fonseca V, Poulter NR, et al. Safety of lixisenatide in patients with type 2 diabetes and acute coronary syndrome: The ELIXA randomised placebo-controlled trial. Lancet Diabetes Endocrinol. 2018;6(11):859-869. https://pubmed.ncbi.nlm.nih.gov/30292589/
Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102. https://pubmed.ncbi.nlm.nih.gov/33068776/
Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2016;18(4):317-332. https://pubmed.ncbi.nlm.nih.gov/26511102/
Christensen M, Calanna S, Holst JJ, Vilsbøll T, Knop FK. Glucose-dependent insulinotropic polypeptide: Blood glucose stabilizing effects in patients with type 2 diabetes. J Clin Endocrinol Metab. 2014;99(3):E418-E426. https://pubmed.ncbi.nlm.nih.gov/24423331/
U.S. Food and Drug Administration. Adlyxin (lixisenatide) injection prescribing information. 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208471orig1s000lbl.pdf
European Medicines Agency. Lyxumia (lixisenatide) product information. 2013. https://www.ema.europa.eu/en/documents/product-information/lyxumia-epar-product-information_en.pdf

Table of Contents